|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
1996
|
|
gptkbp:ATCCode
|
gptkb:J05AE03
|
|
gptkbp:bioavailability
|
75-80%
|
|
gptkbp:CASNumber
|
gptkb:155213-67-5
|
|
gptkbp:category
|
gptkb:antiretroviral_therapy
gptkb:antiviral_drug
|
|
gptkbp:chemicalFormula
|
C37H48N6O5S2
|
|
gptkbp:contraindication
|
severe liver impairment
hypersensitivity to ritonavir
|
|
gptkbp:cost
|
high
|
|
gptkbp:drugClass
|
gptkb:protease_inhibitor
|
|
gptkbp:drugInteraction
|
CYP2D6 inhibitor
CYP3A4 inhibitor
|
|
gptkbp:eliminationHalfLife
|
3-5 hours
|
|
gptkbp:form
|
gptkb:tablet
capsule
oral solution
|
|
gptkbp:genericName
|
gptkb:ritonavir
|
|
gptkbp:indication
|
gptkb:HIV-1
gptkb:HIV-2
|
|
gptkbp:KEGGID
|
gptkb:D00427
|
|
gptkbp:legalStatus
|
expired
Rx-only
|
|
gptkbp:manufacturer
|
gptkb:AbbVie
|
|
gptkbp:mechanismOfAction
|
inhibits HIV protease
|
|
gptkbp:MedlinePlusID
|
a696029
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
B (US)
B3 (Australia)
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:proteinBinding
|
98-99%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL521
392622
DB00503
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
abdominal pain
taste perversion
|
|
gptkbp:storage
|
20°C to 25°C
|
|
gptkbp:synonym
|
gptkb:ABT-538
|
|
gptkbp:UNII
|
QZJ9J9Y1Z5
|
|
gptkbp:usedAs
|
pharmacokinetic booster
|
|
gptkbp:usedFor
|
HIV infection
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:ritonavir
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Norvir
|